Lung cancer continues to be the leading cause of cancer mortality and a serious health
problem despite the numerous advances made in the last decade and the rapid advance of …

Many of the leading developments in management of non-small cell lung cancer (NSCLC)
have been provided by the integration of specific targeted therapies either in combination …

Recent advances in methods of genomic profiling have accelerated our understanding of
the biology of oncologic diseases. Accumulating evidence suggests that both histology and …

Lung cancer is the leading cause of cancer-related mortality in both men and women [1],
with 1.2 million new cases diagnosed every year and with 1 million deaths being recorded …

Recent advances will lead to a rapid expansion of further studies aimed to define the best
way to use targeted agents in NSCLC. Several methodological issues are still open. The …

Conventional treatment of non–small cell lung cancer (NSCLC) has reached a plateau in
improving patient survival, with overall disappointing results. Advances in the singling out of …

Over the last few years, the use of molecular profiling to direct patients to specific targeted
therapies has irrevocably changed how we treat lung cancer. Despite this, many …

Lung cancer remains the leading cause of malignancy-related mortality worldwide, with over
one million cases diagnosed yearly. Non-small-cell lung cancer (NSCLC) accounts for> …

Lung cancer remains the leading cause of cancer-related mortality in both men and women
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …

Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer and represents
a set of histological entities that have an ominous long-term prognosis, for example …